Gilead Sciences Agrees to Acquire German Biotech Tubulis for $3.15 Billion
Gilead Sciences has agreed to acquire the German biotechnology company Tubulis in a deal valued at $3.15 billion, aiming to significantly expand its oncology portfolio. The acquisition focuses on Tubulis's pipeline of antibody-drug conjugates (ADCs), which are designed to deliver chemotherapy more precisely to tumor sites while minimizing damage to healthy cells. Tubulis's lead candidate is currently in mid-stage clinical trials for ovarian and lung cancers, with another ADC in earlier development stages targeting various tumor types. This strategic move bolsters Gilead's capabilities in targeted cancer therapies. The transaction is expected to close by the end of June, pending regulatory approvals. This deal represents a major expansion for the California-based biotech firm into advanced experimental cancer treatments.
Wire timeline
Gilead Sciences Agrees to Acquire German Biotech Tubulis for $3.15 Billion
Gilead Sciences has agreed to acquire the German biotechnology company Tubulis in a deal valued at $3.15 billion, aiming to significantly expand its oncology portfolio. The acquisition focuses on Tubulis's pipeline of antibody-drug conjugates (ADCs), which are designed to deliver chemotherapy more precisely to tumor sites while minimizing damage to healthy cells. Tubulis's lead candidate is currently in mid-stage clinical trials for ovarian and lung cancers, with another ADC in earlier development stages targeting various tumor types. This strategic move bolsters Gilead's capabilities in targeted cancer therapies. The transaction is expected to close by the end of June, pending regulatory approvals. This deal represents a major expansion for the California-based biotech firm into advanced experimental cancer treatments.
Technology - WSJ.com